Cyclosporine bioavailability of Neoral and Sandimmune in white and black de novo renal transplant recipients. Neoral Study Group.
Black renal transplant recipients have inferior graft outcomes when compared to whites. The relative bioavailability of cyclosporine (CsA) with the Sandimmune (SIM) formulation is lower in black recipients when compared to whites. To study relative CsA bioavailability in the Neoral formulation, 18 black and 78 white de novo renal transplant recipients were randomized in a multicenter, double-blind, parallel group study to receive either SIM or Neoral capsules twice a day for 12 weeks. After an overnight fast, CsA whole blood levels (TDx) were collected during 12 hours after the morning dose and 12 hours after the evening dose with a standardized meal. Pharmacokinetic profiles were obtained at the end of weeks 1, 4, 8, and 12. Initial CsA dose was 5 mg/kg twice a day; subsequent doses were titrated to target trough CsA levels. Area under the blood concentration vs. time curve (AUC), peak blood concentration (Cmax) and time to Cmax(Tmax) were obtained from 16 black and 73 white patients. Food conditions (fed and fasting) were averaged, and data was dose-normalized. For black recipients, Neoral was significantly more bioavailable than SIM only during week 1; there was also a consistent trend to higher cyclosporine bioavailability at weeks 4, 8, and 12. For whites, there were significant differences in favor of Neoral at all time periods. No significant differences in relative bioavailability were noted between races for either SIM or Neoral except for a higher Cmax in white patients given Neoral. Neoral is better absorbed than SIM in both blacks and whites. These data suggest that Neoral is the superior CsA preparation for all racial groups.